Epigenetic changes in the rat livers induced by pyrazinamide treatment

Toxicology and Applied Pharmacology

Volumn 225, Issue 3, 2007, Pages 293-299

  Kovalenko, V M ^a   Bagnyukova, T V ^b   Sergienko, O V ^a   Bondarenko, L B ^a   Shayakhmetova, G M ^a   Matvienko, A V ^a   Pogribny, I P ^b  

^a STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

DNA methylation; Liver injury; Pyrazinamide; Rat

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; GLUTATHIONE TRANSFERASE; PROTEIN P16INK4A; PYRAZINAMIDE;

ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFECT; EPIGENETICS; LIVER; LIVER TOXICITY; LONG INTERSPERSED REPEAT; MALE; NONHUMAN; RAT;

ANIMALS; ANTITUBERCULAR AGENTS; BILIRUBIN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTOSINE; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENESIS, GENETIC; GLUTATHIONE S-TRANSFERASE PI; LIVER; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; MALE; PYRAZINAMIDE; RANDOM ALLOCATION; RATS; RATS, WISTAR; TRANSAMINASES;

RATTUS; RATTUS NORVEGICUS;

EID: 36448978274     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.08.011     Document Type: Article

References (44)

1. Björnsson E. Drug-induced liver injury: Hy's rule revisited. Clin. Pharmacol. Ther. 79 (2006) 521-528
2. Chim S.S., Tong Y.K., Chiu R.W., Lau T.K., Leung T.N., Chan L.Y., Oudejans C.B., Ding C., and Lo Y.M. Detection of the placental epigenetic signature of the maspin gene in maternal plasma. Proc. Natl. Acad. Sci. U. S. A. 102 (2006) 14753-14758
3. Durand F., Jebrak G., Pessayre D., Fournier M., and Bernuau J. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Safety 15 (1996) 394-405
4. Eads C.A., and Laird P.W. Combined bisulfite restriction analysis (COBRA). Methods Mol. Biol. 200 (2002) 71-85
5. Farrell G.C. Drugs and steatohepatitis. Semin. Liver Dis. 22 (2002) 185-194
6. INK4a genes in human hepatocellular carcinoma. Liver Int. 25 (2005) 1209-1216
7. Goodman J.I., and Watson R.E. Altered DNA methylation: a secondary mechanism involved in carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 501-525
8. Grieko A., Forgione A., Miele L., Vero V., Greko A.V., Gasbarrini A., and Gasbarrini G. Fatty liver and drugs. Eur. Rev. Med. Pharmacol. Sci. 9 (2005) 261-263
9. Holt M.P., and Ju C. Mechanisms of drug-induced liver injury. AAPS J. 8 (2006) E48-E54
10. Ijaz K., Jereb J.A., Lambert L.A., Bower W.A., Spradling P.R., McElroy P.D., Iademarco M.F., Navin T.R., and Castro K.G. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. Clin. Infect. Dis. 42 (2006) 346-355
11. Jasmer R.M., Saukkonen J.J., Blumberg H.M., Daley C.L., Bernardo J., Vittinghoff E., Jin M., Piao Z., Kim N.G., Park C., Shin E.C., Park J.H., Jung H.J., Kim C.G., and Kim H. p16 is a major inactivation target in hepatocellular carcinoma. Cancer 89 (2000) 60-68
12. Jin M., Piao Z., Kim N.G., Park C., Shin E.C., Park J.H., Jung H.J., Kim C.G., and Kim H. p16 is a major inactivation target in hepatocellular carcinoma. Cancer 89 (2000) 60-68
13. Karpinets T.V., and Foy B.D. Tumorigenesis: the adaptation of mammalian cells to sustained stress environment by epigenetic alterations and succeeding matched mutations. Carcinogenesis 26 (2005) 1323-1334
14. Kramer J.A., Curtiss S.W., Kolaja K.L., Alden C.L., Blomme E.A.G., Curtiss W.C., Davila J.C., Jackson C.J., and Bunch R.T. Acute molecular markers of rodent hepatic carcinogenesis identified by transcription profiling. Chem. Res. Toxicol. 17 (2004) 463-470
15. Lenaerts A.J., Johnson C.M., Marrieta K.S., Gruppo V., and Orme I.M. Significant increases in the levels of liver enzymes in mice treated with anti-tuberculosis drugs. Int. J. Antimicrob. Agents 26 (2005) 152-158
16. Levenson V.V. Biomarkers for early detection of breast cancer: what, when, and where?. Biochim. Biophys. Acta 1770 (2007) 847-856
17. Matsuda Y., and Ichida T. p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis. Med. Mol. Morphol. 39 (2006) 169-175
18. McCarthy M. US guidelines for treatment of latent tuberculosis revised. Lancet 358 (2001) 816
19. McElroy P.D., Ijaz K., Lambert L.A., Jereb J.A., Iademarco M.F., Castro K.G., and Navin T.R. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin. Infect. Dis. 41 (2005) 1125-1133
20. McKillop I.H., Moran D.M., Jin X., and Koniaris L.G. Molecular pathogenesis of hepatocellular carcinoma. J. Surg. Res. 136 (2006) 125-135
21. Moggs J.G., Goodman J.I., Trosko J.E., and Roberts R.A. Epigenetics and cancer: implications for drug discovery and safety assessment. Toxicol. Appl. Pharmacol. 196 (2004) 422-430
22. Moradpour D., and Blum H.E. Pathogenesis of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol 17 (2005) 477-483
23. Nie A.Y., McMillian M., Parker J.B., Leone A., Bryant S., Yieh L., Bittner A., Nelson J., Carmen A., Wan J., and Lord P.G. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol. Carcinog. 45 (2006) 914-933
24. Pogribny I.P., Yi P., and James S.J. A sensitive new method for rapid detection of abnormal methylation patterns in global DNA and within CpG islands. Biochem. Biophys. Res. Commun. 262 (1999) 624-628
25. Pogribny I.P., Ross S.A., Wise C., Pogribna M., Jones E.A., Tryndyak V.P., James S.J., Dragan Y.P., and Poirier L.A. Irreversible global DNA hypomethylation as a key step in hepatocarcinogenesis induced by dietary methyl deficiency. Mutat. Res. 593 (2006) 80-87
26. Pogribny I.P., Ross S.A., Tryndyak V.P., Pogribna M., Poirier L.A., and Karpinets T.V. Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats. Carcinogenesis 27 (2006) 1180-1186
27. Rollins R.A., Haghighi F., Edwards J.R., Das R., Zhang M.Q., Ju J., and Bestor T.H. Large-scale structure of genomic methylation patterns. Genome Res. 16 (2006) 157-163
28. Saukkonen J.J., Cohn D.L., Jasmer R.M., Schenker S., Jereb J.A., Nolan C.M., Peloquin C.A., Gordin F.M., Nunes D., Strader D.B., Bernardo J., Venkataramanan R., and Sterling T.R. An official ATS statement: hepatotoxicity of antitubercolosis therapy. Am. J. Respir. Crit. Care Med. 174 (2006) 935-952
29. Schulz W.A., Steinhoff C., and Florl A.R. Methylation of endogenous human retroelements in health and disease. CTMI 310 (2006) 211-250
30. Skakun N.P., and Tabachuk O.E. Comparative hepatic toxicity of isoniazid, rifampicin and ethambutol. Probl. Tuberk. 10 (1991) 77-79
31. Slivka Iu.I. The hepatotoxic action of pyrazinamide and its effect on lipid peroxidation. Probl. Tuberk. 10 (1988) 47-50
32. Steinmetz K.L., Pogribny I.P., James S.J., and Pitot H.C. Hypomethylation of the rat glutathione-S-transferase {eth} (GSTP) promoter region isolated from methyl-deficient livers and GSTP-positive liver neoplasms. Carcinogenesis 19 (1998) 1487-1494
33. Stravitz R.T., and Sanyal A.J. Drug-induced steatohepatitis. Clin. Liver Dis. 7 (2003) 435-451
34. INK4a in primary rat lung tumors. Mol. Cell. Biol. 17 (1997) 1366-1374
35. Tasduq S.A., Singh K., Satti N.K., Gupta D.K., Suri K.A., and Johri R.K. Terminalia chebula (fruit) prevents liver toxicity caused by sub-chronic administration of rifampicin, isoniazid and pyrazinamide in combination. Human Exp. Toxicol. 25 (2006) 111-118
36. Tchou J.C., Lin X., Freije D., Isaacs W.B., Brooks J.D., Rashid A., De Marzo A.M., Kanai Y., Hirohashi S., and Nelson W.G. GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas. Int. J. Oncol. 16 (2000) 663-676
37. Tryndyak V.P., Kovalchuk O., Muskhelishvili L., Montgomery B., Rodriguez-Juarez R., Melnyk S., Ross S.A., Beland F.A., and Pogribny I.P. Epigenetic reprogramming of liver cells in tamoxifen-induced rat hepatocarcinogenesis. Mol. Carcinog. 46 (2007) 187-197
38. Yang B., Guo M., Herman J.G., and Clark D.P. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am. J. Pathol. 163 (2003) 1101-1107
39. Yew W.W., and Leung C.C. Antituberculosis drugs and hepatotoxicity. Respirology 11 (2006) 699-707
40. Yoder J.A., Walsh C.P., and Bestor T.H. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 13 (1997) 376-378
41. Younossian A.B., Rochat T., Ketterer J.P., Wacker J., and Janssens J.P. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur. Respir. J. 26 (2005) 462-464
42. Valinluck V., and Sowers L.C. Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. Cancer Res. 67 (2007) 5583-5586
43. Watson R.E., and Goodman J.I. Effects of phenobarbital on DNA methylation in GC-rich regions of hepatic DNA from mice that exhibit different levels of susceptibility to liver tumorigenesis. Toxicol. Sci. 68 (2002) 51-58
44. Watson R.E., McKim J.M., Cockerell G.L., and Goodman J.I. The value of DNA methylation analysis in basic, initial toxicity assessments. Toxicol. Sci. 79 (2004) 178-188